For patients who undergo sublobar resection for early stage NSCLC with LN sampling found to have unexpected N2 positive disease, would you consider neoadjuvant chemoimmunotherapy followed by completion lobectomy or proceed directly to adjuvant therapy?

Community
Company
News
Contact Us
Sign in

Topics: Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer

Related Questions

What are your top takeaways in Thoracic Cancers from ASCO 2023?

What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?

What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?

Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?

How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?

Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?

Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?

Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?

How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?

In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?